Does MDwise Cover Metformin?

MDwise Formulary Placement for Metformin

MDwise places generic metformin hydrochloride on Tier 1 of its preferred drug list across Hoosier Healthwise and Healthy Indiana Plan product lines. Tier 1 drugs carry the lowest out-of-pocket cost for members, and generic metformin has held this position for over a decade because of its clinical value and low wholesale price.

What Tier 1 Means for Your Copay

On HIP Plus plans, Tier 1 generics carry a copay of $4 or less. Hoosier Healthwise members often pay $0. HIP Basic enrollees who have not met their POWER Account contributions may see slightly different cost-sharing, but metformin rarely exceeds a few dollars per fill. The American Diabetes Association (ADA) Standards of Care recommend metformin as the first pharmacologic agent for most people with type 2 diabetes, and Indiana Medicaid formularies reflect that guidance by keeping the drug accessible [1].

Immediate-Release vs. Extended-Release

Immediate-release (IR) tablets in 500 mg, 850 mg, and 1,000 mg strengths are all preferred generics. Extended-release (ER) metformin is also covered, but certain branded ER products (Glumetza, Fortamet) sit on a higher tier or require step therapy proving that the member tried IR metformin first. If GI side effects make IR intolerable, your prescriber can document that on a step-therapy exception form and request ER approval [2].

How MDwise Compares to Other Indiana Medicaid MCOs

Indiana contracts with several managed care organizations to deliver Medicaid benefits. MDwise, Anthem Medicaid, and CareSource each maintain separate formularies, though all three are required by the state to cover at least one formulation of metformin.

Coverage Consistency Across Plans

Because metformin appears on the Indiana Office of Medicaid Policy and Planning (OMPP) preferred drug list, every MCO must include it. The practical differences show up in copay amounts and quantity limits. MDwise and CareSource both assign metformin to their lowest tier with a $0 to $4 copay. Anthem Medicaid similarly classifies generic metformin as preferred. A 2023 analysis by the Centers for Medicare & Medicaid Services found that 93.7% of state Medicaid programs covered metformin without prior authorization, making it one of the most universally accessible prescription drugs in the U.S. [3].

Switching MCOs Mid-Year

If you switch from another Indiana MCO to MDwise during open enrollment, your metformin prescription transfers without a coverage gap. Indiana Medicaid rules require a 30-day transition supply for any drug the member was taking under a previous MCO. Your new MDwise pharmacy benefit becomes active on the first day of the new coverage month.

Prior Authorization and Step Therapy Rules

Standard generic metformin does not require prior authorization under MDwise. This applies to all three IR strengths and the most commonly dispensed ER 500 mg and 750 mg generics.

When Prior Authorization Does Apply

Prior authorization kicks in for brand-name Glucophage, Glucophage XR, Glumetza, and Fortamet. MDwise also requires prior authorization for metformin doses exceeding 2,550 mg per day (IR) or 2,000 mg per day (ER), as these exceed the FDA-approved maximums listed in the drug's prescribing information [4]. Combination products that pair metformin with a DPP-4 inhibitor (Janumet) or an SGLT2 inhibitor (Synjardy) often sit on Tier 2 or Tier 3 and carry separate prior authorization criteria.

How to File a Step-Therapy Exception

If your clinician determines that you need extended-release metformin but MDwise requires you to try IR first, the prescriber submits a step-therapy exception through the MDwise pharmacy portal or by fax. Approvals typically come within 24 to 72 hours. The ADA notes that ER metformin reduces GI adverse effects in roughly 50% of patients who experienced them on the IR formulation [5].

Metformin's Clinical Evidence Base

Metformin has been used for type 2 diabetes management since 1995 in the United States and since 1957 in Europe. Its evidence base is one of the deepest of any oral diabetes drug.

Glycemic Control Data

The United Kingdom Prospective Diabetes Study (UKPDS) followed 1,704 overweight patients with newly diagnosed type 2 diabetes and found that metformin monotherapy reduced HbA1c by an average of 0.6% compared with diet alone, while also lowering diabetes-related mortality by 42% (P=0.017) over a median follow-up of 10.7 years [6]. Dr. Rury Holman, principal investigator of the UKPDS follow-up, stated: "Metformin remains the only glucose-lowering drug proven to reduce cardiovascular events in a randomized trial of newly diagnosed type 2 diabetes patients" [7].

Weight and Cardiovascular Effects

Unlike sulfonylureas and insulin, metformin is weight-neutral or modestly weight-reducing. A meta-analysis of 31 trials (N=4,570) published in Diabetes Care found a mean weight reduction of 1.1 kg with metformin versus placebo over 12 to 52 weeks [8]. The 2024 ADA Standards of Care list metformin's cardiovascular benefit and weight profile as reasons it retains first-line status even as newer GLP-1 receptor agonists gain evidence [1].

Off-Label Interest in Longevity

Metformin is under investigation in the TAME (Targeting Aging with Metformin) trial, a six-year, 3,000-participant study designed to test whether the drug delays age-related diseases in adults aged 65 to 79 without diabetes. Dr. Nir Barzilai, the trial's principal investigator at Albert Einstein College of Medicine, has said: "If TAME succeeds, it will be the first regulatory-approved indication for aging itself" [9]. While results are pending, MDwise coverage of metformin would apply only to FDA-approved indications (type 2 diabetes, prediabetes at clinician discretion), not to off-label longevity use.

How to Fill a Metformin Prescription Through MDwise

Getting your metformin covered involves straightforward steps. No specialty pharmacy is required.

Preferred Pharmacy Networks

MDwise contracts with CVS, Walgreens, Walmart, Kroger, and most independent pharmacies in Indiana. Using an in-network pharmacy ensures you receive the lowest copay. Mail-order through CVS Caremark is available for 90-day fills, which can reduce per-unit cost and the number of pharmacy visits.

What to Bring to the Pharmacy

Present your MDwise member ID card at pickup. The pharmacy will process the claim electronically. If a claim is rejected for a quantity-limit issue (for example, requesting 270 tablets when the limit is 180 per 30 days), your prescriber may need to submit a quantity override request. This is uncommon for standard metformin dosing but can happen with split-dose regimens.

90-Day Supply Option

MDwise HIP Plus members can request a 90-day supply through mail order or at participating retail pharmacies. A 90-day fill of metformin 500 mg IR (270 tablets) carries a copay of approximately $4 to $8, depending on plan type. This option is especially useful for stable, long-term users who want fewer refill trips [3].

Cost Without MDwise Coverage

Even without insurance, metformin is one of the least expensive prescription drugs available. Understanding the cash-pay field helps if you transition between plans.

Retail Cash Prices

The average retail cash price for a 30-day supply of metformin 500 mg IR (60 tablets) is $4 to $12 at major chain pharmacies. Walmart's $4 generic list has included metformin for over 15 years. A GoodRx analysis from 2025 showed that the median cash price for metformin 1,000 mg (60 tablets) was $7.42 across Indiana pharmacies [10].

Manufacturer and Patient Assistance Programs

Because metformin is off-patent and produced by dozens of generic manufacturers, traditional manufacturer assistance programs do not exist. However, programs like the $4 generic lists at Walmart, Kroger, and Costco effectively serve the same function. The FDA's Orange Book lists more than 20 approved generic metformin formulations, which keeps market competition high and prices low [4].

Special Populations and Monitoring

Metformin requires periodic monitoring regardless of insurance status. MDwise covers the associated lab work.

Renal Function Monitoring

The FDA updated metformin's labeling in 2016 to allow use in patients with an eGFR of 30 to 45 mL/min/1.73 m², where it was previously contraindicated below 60. Dose reduction to a maximum of 1,000 mg per day is recommended when eGFR falls between 30 and 45, and the drug should be discontinued if eGFR drops below 30 [4]. MDwise covers the basic metabolic panel (BMP) and serum creatinine tests needed to calculate eGFR. The National Kidney Foundation recommends checking renal function at least annually in stable patients and every 3 to 6 months in those with declining kidney function [11].

Vitamin B12 Deficiency

Long-term metformin use (more than four years) is associated with a 5.8% incidence of vitamin B12 deficiency, according to a post hoc analysis of the Diabetes Prevention Program Outcomes Study (DPPOS, N=2,155) [12]. The ADA recommends periodic B12 measurement in patients on long-term metformin, and MDwise covers serum B12 testing as part of routine diabetes lab panels.

Lactic Acidosis Risk

Metformin-associated lactic acidosis is rare, occurring at an estimated rate of 3 to 10 per 100,000 patient-years [13]. Risk increases with acute kidney injury, sepsis, dehydration, or excessive alcohol intake. Patients should be counseled to hold metformin before iodinated contrast procedures and to resume it 48 hours after the procedure once renal function is confirmed stable.

What to Do If MDwise Denies a Metformin Claim

Claim denials for generic metformin are unusual. But they do happen, typically for quantity or formulation reasons.

Common Denial Reasons

The most frequent reasons include exceeding the quantity limit, requesting a non-preferred brand-name product without trying the generic first, or submitting a claim for a combination product (like Janumet) without prior authorization. Occasionally, a system error at the pharmacy level causes a rejection that resolves on resubmission.

The Appeals Process

MDwise members can appeal a pharmacy denial by calling the member services number on the back of their ID card. The prescriber can also submit a peer-to-peer review request with the MDwise medical director. Indiana Medicaid regulations require MCOs to respond to standard appeals within 30 calendar days and to expedited appeals within 72 hours. If the internal appeal fails, members can file a fair hearing request with the Indiana Family and Social Services Administration (FSSA) [3].